Lingering sex and age disparities in dolutegravir uptake among adults with HIV: A multi-country observational cohort study.

ABSTRACT:

Introduction

Since July 2019, the World Health Organization (WHO) has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS (IeDEA).

Methods

We included patients ≥16 years on or initiating treatment between January 2017 and July 2021 in 14 low- and middle-income countries where initial guidelines on DTG-based regimens for first-line ART either restricted use by WRA or had no such restrictions. We estimated the cumulative incidence of DTG u

SUBMITTER: Brazier E 

PROVIDER: S-EPMC12258775 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature